Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The viral gastroenteritis market dynamics are governed by a complicated mix of medical, epidemiological and pharmacological factors which in turn determine such factors as the necessity of early and accurate diagnostics and the choice of appropriate therapy. Viral Gastroenteritis, which is abundant gagging, nausea, and a runny stomach, is one of the most widespread infections poisoned by viruses such as norovirus and rotavirus (worldwide). The market is mainly propelled by the existence of a pretty high incidence of viral gastroenteritis, and thus the necessity of quick infections diagnostics and supportive care for the control and prevention of their spread.
The role of terror of Australian Bush Fire Disaster diagnosis technologies in the market dynamics is unquestionably important. The necessity for first-response kits that are available almost everywhere, point-of-care and help to immediately identify and eradicate the viruses, has been on the increase as time rolls in. Molecular diagnostics techniques, immunoassays, and quick test performed at the point of care contribute greatly to efficient diagnosis which makes the healthcare providers to trigger relevant intervention measures immediately. The marketentails the crucial role of rapid and accurate diagnostics of viral gastroenteritis which helps in efficient management of cases and curbing further spread.
Viral Gasteroenteritis market is driven by a variety of epidemiological factors. The transmission nature of these viral infections with their ability to be easily spread in different setup, irrespective, whether the settings are healthcare facilities, schools, community, environments influence the demand for effective countermeasures. Given its ability to affect people of all age groups, like through the virus gastroenteritis, the market becomes wide, which need solutions appropriate for many service takers and their age.
While drug interventions and supportive care strategies equally make for an essential role in market dynamics of the Viral Gastroenteritis, so does the emergence of innovative drugs. Now, the treatment regime currently consists of the use of non-specific antiviral drugs and the cure of symptoms plus prevention of dehydration that may lead to complications. The pharmaceutical companies are investing in the research and development to show the possibility of antiviral medicines and vaccines with the acknowledgement that a dense pattern of targeted viral gastroenteritis therapeutic interventions may be needed.
The market of Viral Gastroenteritis is rather competitive and diverse: there are pharma companies, diagnostic manufacturers, and healthcare providers who provide a good choice for consumers. In the bid to make a breakthrough, pharmaceutical companies are conducting their own research and are developing accurate diagnostic kits, antiviral drugs, and effective vaccines. Partnerships of pharmaceutical businesses, research facilities, and public health organizations help to ensure that research is highly developed and the effective strategies for both managing and preventing viral enteritis are elaborated.
Viral Gastroenteritis Market Highlights:
Global Viral Gastroenteritis Market Overview
The Viral Gastroenteritis Market Size was valued at USD 47.31 Billion in 2023. The Global Viral Gastroenteritis industry is projected to grow from USD 49.63 Billion in 2024 to USD 72.77 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.10% during the forecast period (2024 - 2032).
Viral gastroenteritis, also known as stomach flu, is inflammation of the lining of the stomach, small intestine, and large intestine.
There are a number of viruses leading viral gastroenteritis such as norovirus, rotavirus, astrovirus and enteric adenovirus. Norovirus and rotavirus are the most common causes of this disease. This disease is transmitted through direct contact with the patient, and contaminated water or food. The main focus of treating the disease is rehydration by drinking enough water or fluids.
Viral Gastroenteritis Market Trends
The market for viral gastroenteritis is driven by an increasing prevalence of gastrointestinal diseases, availability of cost effective treatment and extensive research and development activities in internal medicine Furthermore, there is an increasing demand for the new drugs for the treatment of the disease.
Bacterial resistance to commonly used antibiotics such as penicillin and amoxicillin may be the leading restrain for the growth of the market. Fierce competition among key market players acts as a barrier for the new entrant in the market.
According to the World Health Organization (WHO), diarrheal diseases are a major cause of hospitalizations and child deaths globally.
Viral Gastroenteritis Market Segment Insights
The global viral gastroenteritis market is segmented on the basis of type of virus, diagnosis, drugs, indication, and end user.
On the basis of type of virus, market is segmented into norovirus, rotavirus, astrovirus, and enteric adenovirus.
On the basis of diagnosis, the market is segmented into physical examination and rapid stool test.
On the basis of drugs, the market is segmented into Antibiotics, antacids, laxatives, antimotility agents and others. Other drugs are antiemetics and chemotherapy drugs.
On the basis of indication, the market is segmented into watery diarrhea, vomiting, abdominal cramps and pain and others.
On the basis of end user, the market is segmented into hospitals, clinics, pharmaceutical companies, diagnostic centers, ambulatory care centers and others.
Viral Gastroenteritis Regional Insights
America is the largest market for viral gastroenteritis owing to rising prevalence of viral gastroenteritis in the U.S., especially among the pediatric population. According to the Center For Disease Control And Prevention (CDC), each year on average in the United States, there are 19 to 21 million cases of acute gastroenteritis.
Europe is the second largest market for viral gastroenteritis. According to an article published in the journal of Clinical Virology, in Europe, acute infectious gastroenteritis is one of the major causes for substantial morbidity and economic loss.
In Asia Pacific, the common cause of severe gastroenteritis in children less than 5 years of age, is rotavirus. The market in Asia Pacific is driven by an increasing demand for rapid diagnostic tests for gastrointestinal diseases and increasing awareness about available treatment options for viral gastroenteritis. Also, growing investments in the field of life science research and demand for advanced therapies for the treatment of gastrointestinal diseases in developing nations such as China and India will propel the growth of the Asia Pacific market.
The Middle East & Africa also show a steady rise in the market owing to increasing number of cases of diarrhea due to viral infection.
Key Players in the Global Viral Gastroenteritis Market
- Valeant Pharmaceuticals International Inc. (U.S.)
- Janssen Global Services, LLC (U.S.)
- Takeda Pharmaceutical (Japan)
- Bayer AG (Germany)
- Sanofi (France)
- Allergan (Ireland)
- GlaxoSmithKline (U.S.)
- Abbott (U.S.)
- AstraZeneca (U.K)
Research Methodology
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
Intended Audience
- Gastrointestinal Drug Manufacturers
- Gastrointestinal Drug Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
